List of Excipients in API ALPELISIB
✉ Email this page to a colleague
Excipients in NDA-approved (novel) drugs containing ALPELISIB
| Company | Tradename | Ingredient | NDC | Excipient | Potential Generic Entry |
|---|---|---|---|---|---|
| Novartis Pharmaceuticals Corporation | PIQRAY | alpelisib | 0078-0708 | CELLULOSE, MICROCRYSTALLINE | 2033-04-29 |
| Novartis Pharmaceuticals Corporation | PIQRAY | alpelisib | 0078-0708 | FERRIC OXIDE RED | 2033-04-29 |
| Novartis Pharmaceuticals Corporation | PIQRAY | alpelisib | 0078-0708 | FERROSOFERRIC OXIDE | 2033-04-29 |
| Novartis Pharmaceuticals Corporation | PIQRAY | alpelisib | 0078-0708 | HYPROMELLOSE | 2033-04-29 |
| Novartis Pharmaceuticals Corporation | PIQRAY | alpelisib | 0078-0708 | MAGNESIUM STEARATE | 2033-04-29 |
| Novartis Pharmaceuticals Corporation | PIQRAY | alpelisib | 0078-0708 | MANNITOL | 2033-04-29 |
| Novartis Pharmaceuticals Corporation | PIQRAY | alpelisib | 0078-0708 | POLYETHYLENE GLYCOL 4000 | 2033-04-29 |
| >Company | >Tradename | >Ingredient | >NDC | >Excipient | >Potential Generic Entry |
Detailed excipient profiles for ALPELISIB
Excipient focus: CELLULOSE, MICROCRYSTALLINE
ALPELISIB drug variants containing CELLULOSE, MICROCRYSTALLINE
| Company | Ingredient | NDC |
|---|---|---|
| Novartis Pharmaceuticals Corporation | alpelisib | 0078-0708 |
| Novartis Pharmaceuticals Corporation | alpelisib | 0078-1021 |
| >Company | >Ingredient | >NDC |
ALPELISIB drug variants not containing CELLULOSE, MICROCRYSTALLINE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: FERRIC OXIDE RED
ALPELISIB drug variants containing FERRIC OXIDE RED
| Company | Ingredient | NDC |
|---|---|---|
| Novartis Pharmaceuticals Corporation | alpelisib | 0078-0708 |
| Novartis Pharmaceuticals Corporation | alpelisib | 0078-1021 |
| >Company | >Ingredient | >NDC |
ALPELISIB drug variants not containing FERRIC OXIDE RED
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: FERRIC OXIDE YELLOW
ALPELISIB drug variants containing FERRIC OXIDE YELLOW
| Company | Ingredient | NDC |
|---|---|---|
| Novartis Pharmaceuticals Corporation | alpelisib | 0078-1021 |
| >Company | >Ingredient | >NDC |
ALPELISIB drug variants not containing FERRIC OXIDE YELLOW
| Company | Ingredient | NDC |
|---|---|---|
| Novartis Pharmaceuticals Corporation | alpelisib | 0078-0708 |
| >Company | >Ingredient | >NDC |
Excipient focus: FERROSOFERRIC OXIDE
ALPELISIB drug variants containing FERROSOFERRIC OXIDE
| Company | Ingredient | NDC |
|---|---|---|
| Novartis Pharmaceuticals Corporation | alpelisib | 0078-0708 |
| >Company | >Ingredient | >NDC |
ALPELISIB drug variants not containing FERROSOFERRIC OXIDE
| Company | Ingredient | NDC |
|---|---|---|
| Novartis Pharmaceuticals Corporation | alpelisib | 0078-1021 |
| >Company | >Ingredient | >NDC |
Excipient focus: HYPROMELLOSE
ALPELISIB drug variants containing HYPROMELLOSE
| Company | Ingredient | NDC |
|---|---|---|
| Novartis Pharmaceuticals Corporation | alpelisib | 0078-0708 |
| Novartis Pharmaceuticals Corporation | alpelisib | 0078-1021 |
| >Company | >Ingredient | >NDC |
ALPELISIB drug variants not containing HYPROMELLOSE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: MAGNESIUM STEARATE
ALPELISIB drug variants containing MAGNESIUM STEARATE
| Company | Ingredient | NDC |
|---|---|---|
| Novartis Pharmaceuticals Corporation | alpelisib | 0078-0708 |
| Novartis Pharmaceuticals Corporation | alpelisib | 0078-1021 |
| >Company | >Ingredient | >NDC |
ALPELISIB drug variants not containing MAGNESIUM STEARATE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: MANNITOL
ALPELISIB drug variants containing MANNITOL
| Company | Ingredient | NDC |
|---|---|---|
| Novartis Pharmaceuticals Corporation | alpelisib | 0078-0708 |
| Novartis Pharmaceuticals Corporation | alpelisib | 0078-1021 |
| >Company | >Ingredient | >NDC |
ALPELISIB drug variants not containing MANNITOL
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: POLYETHYLENE GLYCOL 4000
ALPELISIB drug variants containing POLYETHYLENE GLYCOL 4000
| Company | Ingredient | NDC |
|---|---|---|
| Novartis Pharmaceuticals Corporation | alpelisib | 0078-0708 |
| Novartis Pharmaceuticals Corporation | alpelisib | 0078-1021 |
| >Company | >Ingredient | >NDC |
ALPELISIB drug variants not containing POLYETHYLENE GLYCOL 4000
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: SODIUM STARCH GLYCOLATE TYPE A POTATO
ALPELISIB drug variants containing SODIUM STARCH GLYCOLATE TYPE A POTATO
| Company | Ingredient | NDC |
|---|---|---|
| Novartis Pharmaceuticals Corporation | alpelisib | 0078-0708 |
| Novartis Pharmaceuticals Corporation | alpelisib | 0078-1021 |
| >Company | >Ingredient | >NDC |
ALPELISIB drug variants not containing SODIUM STARCH GLYCOLATE TYPE A POTATO
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: TALC
ALPELISIB drug variants containing TALC
| Company | Ingredient | NDC |
|---|---|---|
| Novartis Pharmaceuticals Corporation | alpelisib | 0078-0708 |
| Novartis Pharmaceuticals Corporation | alpelisib | 0078-1021 |
| >Company | >Ingredient | >NDC |
ALPELISIB drug variants not containing TALC
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: TITANIUM DIOXIDE
ALPELISIB drug variants containing TITANIUM DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| Novartis Pharmaceuticals Corporation | alpelisib | 0078-0708 |
| Novartis Pharmaceuticals Corporation | alpelisib | 0078-1021 |
| >Company | >Ingredient | >NDC |
ALPELISIB drug variants not containing TITANIUM DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
© Copyright 2002-2024 thinkBiotech LLC
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Generic Entry Opportunies 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Generic Entry Opportunies 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Preferred Citation:
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Links
Follow DrugPatentWatch:
